New England Journal of Medicine Ahead of Print: Latest Research and Clinical Advances

On April 16, 2026, The New England Journal of Medicine published a perspective article titled “Closing the Evidence Gap for Drugs in Children — Measures to Strengthen the Pediatric Research Equity Act,” authored by Amy W. Stimpfel and Maja Djukic. The article examines current limitations in pediatric drug research and proposes actionable steps to enhance the Pediatric Research Equity Act (PREA) to better address the lack of safety and efficacy data for medications used in children.

The authors highlight that despite PREA’s requirement for pediatric assessments of certain drugs, significant gaps remain in the evidence base for medications prescribed to infants, children, and adolescents. They note that many drugs used in pediatric populations lack adequate labeling information regarding dosing, effectiveness, and potential adverse effects, which poses risks to young patients and challenges for clinicians.

Stimpfel and Djukic identify several structural barriers contributing to this evidence gap, including inconsistent enforcement of PREA requirements, loopholes that allow sponsors to defer or avoid pediatric studies, and insufficient incentives for conducting research in rare pediatric conditions. They argue that these limitations undermine the original intent of PREA, which was enacted in 2003 to ensure that children receive medications with proven safety and efficacy profiles.

To strengthen PREA, the authors recommend closing regulatory loopholes that permit waivers or deferrals without sufficient justification, increasing transparency in pediatric study requirements and outcomes, and enhancing enforcement mechanisms to ensure compliance. They also suggest expanding PREA’s scope to include more drug classes and biological products currently exempt from pediatric assessment requirements.

The perspective emphasizes the importance of leveraging real-world data and innovative trial designs, such as adaptive clinical trials and biomarker-based approaches, to make pediatric research more feasible and ethical. The authors note that integrating these methods could reduce the burden on young participants while still generating robust evidence to inform prescribing practices.

Stimpfel and Djukic call for greater collaboration among the U.S. Food and Drug Administration, the National Institutes of Health, academic institutions, and pharmaceutical companies to prioritize pediatric research needs. They stress that sustained investment in pediatric pharmacology and clinical trial infrastructure is essential to close the evidence gap and protect the health of children receiving medical treatments.

The article concludes that strengthening PREA through targeted legislative and regulatory reforms would significantly improve the availability of reliable drug information for pediatric populations. By ensuring that medications used in children are thoroughly studied, the authors argue that healthcare providers can make safer, more informed decisions, ultimately leading to better health outcomes for young patients.